Recent data reveals that new obesity drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, may also help reduce alcohol and smoking habits, highlighting their potential role in addiction treatment. – Bloomberg (26 June 2024)
Although 1 in 6 Americans have an addiction, the pharmaceutical industry prioritises obesity treatments, which are expected to generate $93bn in sales by 2030A.
small study presented at an addiction science meeting indicated that semaglutide, an ingredient Academic and government researchers continue to investigate GLP-1 drugs for various addictions, including tobacco and opioids, due to their ability to reduce cravings and block withdrawal symptoms.